Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
In a study designed to investigate the biological relevance of PARP1 in multiple myeloma (MM), data revealed a significant correlation between increased PARP1 mRNA expression and poor prognosis…
Corey Cutler, MD, MPH, medical director of the Adult Stem Cell Transplantation Center at Dana-Farber Cancer Institute, discusses Blood and Marrow Clinical Trials Network Study 1102, comparing patients…
Phase 3 ASCERTAIN Trial Shows Promising Results with Oral Decitabine and Cedazuridine Combination for the Treatment of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia
Naval Daver, MD, University of Texas MD Anderson Cancer Center, shares recent work on combination magrolimab, a CD47-targeting monoclonal antibody, and the hypomethylating agent azacitidine. The azacitidine and…
Sergio Rutella, MD, PhD, FRCPath, hematologist and professor of cancer immunotherapy at the John van Geest Cancer Research Centre, reports new findings from his work on acute myeloid…
Thomas Prebet, MD, PhD, Yale School of Medicine, previews recent advancements and treatment options for acute myeloid leukemia (AML) patients with TP53, IDH, and FLT3 mutations. Dr. Prebet…
Andrew Krivoshik, MD, PhD, Oncology Therapeutic Area Head at Astellas Pharma, discusses acute myeloid leukemia (AML) in the context of the COVID-19 pandemic. The prevalence of healthcare disparities…
Andrew Krivoshik, MD, PhD, Oncology Therapeutic Area Head at Astellas Pharma, reviews treatment options for acute myeloid leukemia (AML) patients. Dr. Krivoshik states that, while patients traditionally receive…
Arkadiusz Z. Dudek, MD, medical oncologist at Regions Hospital Care Center in St. Paul, Minnesota, discusses a phase 2 trial of nivolumab plus ramucirumab in previously treated mesothelioma…
Researchers from UC Davis Comprehensive Cancer Center discuss results from their recent study on long term complications adolescents and young adults face after treatment for acute myeloid leukemia…
